AbCellera CBO Neil Berkley departs; separation deal includes salary continuation, equity acceleration

AbCellera Biologics Inc.

Neil Berkley left as Chief Business Officer effective June 29, 2022.
Receives 12 months base salary ($450,000/yr) paid over 12 months, plus $173,710 cash payment.
AbCellera accelerates vesting of 17,500 RSUs; shares issued on Aug 11, 2022 after trading restriction.
Company pays COBRA premiums through July 1, 2023 or earlier if new job obtained.
Separation agreement includes non-disparagement, non-solicitation, and confidentiality covenants.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Neil Berkley

Chief Business Officer

ABCL · AbCellera Biologics Inc.

Effective: 2022-06-29
Filed: July 19, 2022, 7:59 PM ET

the departure of Neil Berkley, its Chief Business Officer, from the Company effective June 29, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil Berkley departed as Chief Business Officer at AbCellera Biologics Inc..

Action: departed
Role: Chief Business Officer

Exact text from the filing

the departure of Neil Berkley, its Chief Business Officer, from the Company effective June 29, 2022.

View on SEC.gov

AbCellera Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-025922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.